Recently, many studies have found that inhibition of bromodomain-containing protein 4 (BRD4) with pharmacological BET-specific bromodomain (BD) inhibitors can effectively block MYC expression in multiple myeloma, acute myeloid leukemia, and Burkitt's lymphoma 27-29. This evidence concerns the gene DNER and plasma cell myeloma.